Patents by Inventor David Cushing

David Cushing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240304539
    Abstract: The disclosed technology generally relates to metallization of substrates, and more particularly to selective metallization of ceramic substrates without using a magnetic metal such as nickel (Ni). A ceramic package configured to house an electronic device. The ceramic package comprises a ceramic substrate and a non-magnetic metallization stack formed on the ceramic substrate. The non-magnetic metallization stack comprises a base metal layer formed on the ceramic substrate, a palladium (Pd)-based layer formed on the base metal layer, and a gold (Au)-based layer formed on the Pd-based layer. The non-magnetic metallization stack does not include a magnetic metal layer.
    Type: Application
    Filed: March 7, 2024
    Publication date: September 12, 2024
    Inventors: Aaron Fitzsimmons, William T. Minehan, David A. Cushing, Kera Jones
  • Patent number: 11235877
    Abstract: A payload mechanism for a vehicle is provided.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: February 1, 2022
    Assignee: BAE Systems plc
    Inventors: James David Cushing, Andrew Charles White
  • Publication number: 20210354823
    Abstract: A payload mechanism for a vehicle is provided.
    Type: Application
    Filed: October 29, 2019
    Publication date: November 18, 2021
    Applicant: BAE Systems plc
    Inventors: James David CUSHING, Andrew Charles WHITE
  • Patent number: 9873704
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 23, 2018
    Assignee: AMGEN INC.
    Inventors: Minna Bui, Yi Chen, Timothy David Cushing, Jason A. Duquette, Benjamin Fisher, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Michael G. Johnson, Brian Lucas
  • Publication number: 20160333017
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: July 26, 2016
    Publication date: November 17, 2016
    Applicant: AMGEN INC.
    Inventors: Minna BUI, Yi CHEN, Timothy David CUSHING, Jason A. DUQUETTE, Benjamin FISHER, Felix GONZALEZ LOPEZ DE TURISO, Xiaolin HAO, Xiao HE, Michael G. JOHNSON, Brian LUCAS
  • Patent number: 9081849
    Abstract: A multidimensional query results processing system for translating output of an execution of a multidimensional query into a data result set that reflects the semantics of an entity/relationship schema report specification is provided. The system comprises a result set description generation module for producing a result set description that reflects the semantics of the report specification, a tabular row generation module for converting the results of the single multi-dimensional query into a collection of rows of data, a tabular summary level calculation module for calculating a summarization level of a row a data, a tabular header row generation module for producing a header row to include in the row of data, and a cross-tabulated result generation module for converting the results of the single multi-dimensional query into a result set that matches the semantics of the report specification.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: July 14, 2015
    Assignee: International Business Machines Corporation
    Inventors: David Cushing, Marius Cosma, Neil Warner, Helmut Beffert
  • Patent number: 8835432
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: September 16, 2014
    Assignee: Amgen Inc.
    Inventors: Minna Bui, Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Brian Lucas
  • Publication number: 20140206694
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: Amgen Inc.
    Inventors: Minna Bui, Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Brian Lucas
  • Patent number: 8765940
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphob
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: July 1, 2014
    Assignee: Amgen Inc.
    Inventors: Matthew Brown, Yi Chen, Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiao He, Todd J. Kohn, Julia Winslow Lohman, Vatee Pattaropong, Jennifer Seganish, Youngsook Shin, Jillian L. Simard
  • Patent number: 8765768
    Abstract: Substituted bicyclic heteroaryls having the general formula (I) and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p1 108 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML), Myelodysplastic syndrome (MDS), myelo-proliferative diseases (MPD), Chronic Myeloid
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: July 1, 2014
    Assignee: Amgen Inc.
    Inventors: Timothy David Cushing, Julia Winslow Lohman, Youngsook Shin
  • Patent number: 8754089
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphob
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: June 17, 2014
    Assignee: Amgen Inc.
    Inventors: Timothy David Cushing, Xiaolin Hao, Julia Winslow Lohman, Youngsook Shin
  • Patent number: 8716290
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: May 6, 2014
    Assignee: Amgen Inc.
    Inventors: Minna Bui, Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Brian Lucas
  • Publication number: 20140081822
    Abstract: A method and system for performing a batch auction whereby a series of orders, according to a variety of predetermined order types, are generated by qualified market participants and communicated to an auction system. The auction system takes into account each order and its impact upon relative supply and demand to determine by a preset algorithm a price and share transaction quantity. Trades are executed at the price, and a portion of the transaction quantity is allocated to each investor on a fair basis dependent upon their initial orders. In embodiments of the present invention, the auction system uses a computer system or network designed to automatically perform one or more steps of the above method. Such a system is preferably connected to one or more ECNs such that non-executed shares can be automatically sent to outside sources for execution.
    Type: Application
    Filed: September 9, 2013
    Publication date: March 20, 2014
    Applicant: ITG SOFTWARE SOLUTIONS, INC.
    Inventor: David CUSHING
  • Publication number: 20140030688
    Abstract: One method for communicating recommendations over a data network, comprising the steps of an initiating participant asking a question of a primary responder over the network; the primary responder providing a first answer to the question over the network and recommending at least one secondary responder to provide an answer to the question; each of the at least one secondary responder providing a second answer to the question over the network and further recommending at least one tertiary responder to provide an answer to the question; the at least one tertiary responder providing a third answer to the question over the network; and, a computer receiving each of the first, second and third answers and displaying them in a hierarchical manner.
    Type: Application
    Filed: July 25, 2013
    Publication date: January 30, 2014
    Applicant: ARMITAGE SHEFFIELD, LLC
    Inventors: Christopher Lolli, James Monte Henige, David Cushing, Thomas Galbreath, Alan Helgeson, Michael Brucher, Frank O'Connor
  • Patent number: 8633313
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: January 21, 2014
    Assignee: Amgen Inc.
    Inventors: Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Youngsook Shin
  • Patent number: 8575183
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: November 5, 2013
    Assignee: Amgen Inc.
    Inventors: Timothy David Cushing, Jason A. Duquette, Xiao He, Julia Lohman, Youngsook Shin
  • Publication number: 20130267524
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: April 4, 2013
    Publication date: October 10, 2013
    Applicant: Amgen Inc.
    Inventors: Minna Bui, Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Brian Lucas
  • Publication number: 20130267526
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphobl
    Type: Application
    Filed: December 16, 2011
    Publication date: October 10, 2013
    Applicant: Amgen, Inc.
    Inventors: Yi Chen, Timothy David Cushing, Benjamin Fisher, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Youngsook Shin
  • Patent number: 8533100
    Abstract: A method and system for performing a batch auction whereby a series of orders, according to a variety of predetermined order types, are generated by qualified market participants and communicated to an auction system. The auction system takes into account each order and its impact upon relative supply and demand to determine by a preset algorithm a price and share transaction quantity. Trades are executed at the price, and a portion of the transaction quantity is allocated to each investor on a fair basis dependent upon their initial orders. In embodiments of the present invention, the auction system uses a computer system or network designed to automatically perform one or more steps of the above method. Such a system is preferably connected to one or more ECNs such that non-executed shares can be automatically sent to outside sources for execution.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: September 10, 2013
    Assignee: ITG Software Solutions, Inc.
    Inventor: David Cushing
  • Publication number: 20130231352
    Abstract: Substituted bicyclic heteroaryls having the general formula (I) and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p1 108 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML), Myelodysplastic syndrome (MDS), myelo-proliferative diseases (MPD), Chronic Myeloid
    Type: Application
    Filed: November 17, 2011
    Publication date: September 5, 2013
    Applicant: Amgen Inc.
    Inventors: Timothy David Cushing, Julia Winslow Lohman, Youngsook Shin